Wyss Institute for Biologically Inspired Engineering

First Mice Engineered to Survive COVID-19 Like Young, Healthy Humans

Retrieved on: 
Wednesday, November 1, 2023
Wyss Institute, Neoplasm, ACE, ACE2, National Institutes of Health, Adenine, Opentrons, CDI, TP53, Obesity, Biochemistry, Human, DNAS, CRISPR, Genetics, G.H. Raisoni Department of Microbiology and Biotechnology, NYU Langone Health, Diabetes, Q-system (genetics), Doctor of Philosophy, Infection, Genetic code, Fungus, Cell, Wyss Institute for Biologically Inspired Engineering, Research, NYU, Mouse, Sol, Genome, COVID-19, Cancer, Guanine, New York University Grossman School of Medicine, Gene, Pharmacology, Cytosine, Patient, Bangladesh Technical Education Board, Mutation, AG, DNA, Vaccine, Pathology, Nature

NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.

Key Points: 
  • NEW YORK, Nov. 1, 2023 /PRNewswire/ -- Researchers have genetically engineered the first mice that get a human-like form of COVID-19, according to a study published online November 1 in Nature.
  • The mice with this genetic change developed symptoms similar to young humans infected with the virus causing COVID-19, instead of dying upon infection as had occurred with prior mouse models.
  • "This has been a major missing piece in efforts to develop new drugs against this virus."
  • Boeke also receives consulting fees and royalties from OpenTrons, and holds equity in the company.

Foresight Institute Announces 2023 Feynman Prize Winners

Retrieved on: 
Sunday, October 29, 2023
Wyss Institute, Foresight Institute, MacArthur, MIT, Nanotechnology, Collins, Therapy, Life, European Research Council, CRISPR, Broad Institute, Doctor of Philosophy, Research, Internet, Wyss Institute for Biologically Inspired Engineering, Multimedia, Yale University, American Physical Society, Fairy, Feynman Prize in Nanotechnology, University of Luxembourg, Machine learning, Physics, Nanostructure, Teaching, Nobel Prize in Chemistry, University, Nobel Prize, Van der Waals, Synthetic biology, Harvard University, Château, SAN, DNA, Creative industries, Pharmaceutical industry, Auction, Chemistry

SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies. Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies. Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.

Key Points: 
  • SAN FRANCISCO, Oct. 29, 2023 /PRNewswire-PRWeb/ -- Established in 1986, Foresight Institute is a pioneering non-profit organization dedicated to the advancement of molecular manufacturing and transformative technologies.
  • Navigating scientific areas often seen as too ambitious for traditional institutions, Foresight Institute is committed to shaping the long-term future of life through these technologies.
  • Awarded since 1993, Foresight Institute's Feynman Prizes celebrate both established and emerging talents in the field of nanotechnology, embodying their vision of steering transformative technologies to benefit humanity.
  • Foresight Institute also bestows the Distinguished Student Award, spotlighting an upcoming individual for their exceptional work in advancing nanotechnology development and understanding.

EnPlusOne Biosciences to Attend and Present Poster at OTS Annual Meeting

Retrieved on: 
Friday, October 20, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Wyss Institute, Harvard–MIT Program in Health Sciences and Technology, MIT, OTS, Harvard Medical School, CSO, Manuscript, Engineering, Outline of health sciences, Therapy, Wyss Institute for Biologically Inspired Engineering, RNA, George Church, Doctor of Philosophy, Oligonucleotide, Enzyme, Harvard University, Poster, NTS Sessions 1–4, Wyss, Fine chemical

The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.

Key Points: 
  • The company, which is a bronze level sponsor of the annual meeting, will also be delivering a poster presentation that highlights recent technical developments on its propriety enzymatic RNA oligonucleotide synthesis technology.
  • The poster presentation is entitled “A Platform for Controlled Enzymatic Synthesis of RNA Oligonucleotides“ and will be delivered by Dominic Rainone, an Associate Scientist at EnPlusOne Biosciences, during Poster Session 1, which begins at 17:00 on October 23rd.
  • Additional technical data from this poster can also be found in EnPlusOne’s recent manuscript pre-print available online.
  • Likewise, we’ve been very strong supporters of OTS and its mission to bring the field of oligonucleotides to its full therapeutic potential.

BD² ANNOUNCES $18 MILLION IN GRANTS TO UNDERSTAND BIOLOGY OF BIPOLAR DISORDER

Retrieved on: 
Tuesday, September 19, 2023
Yale University, Science, Therapy, Stanford University, Harvard University, Coalition, Sleep, Research, ASAP, Mount Sinai, Bangladesh Technical Education Board, Doctor of Philosophy, Bipolar disorder, Nebraska Religious Coalition for Science Education, Discovery, Parkinson's disease, Wyss Institute, Icahn School of Medicine at Mount Sinai, Milken Institute, Biology, Wyss Institute for Biologically Inspired Engineering, Gene, Chair, Research fellow, Management, Pharmaceutical industry, Lithium, New York Genome Center, MD, Medicine

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- BD²: Breakthrough Discoveries for Thriving with Bipolar Disorder today announced its first round of Discovery Research grants, totaling $18 million, bringing greater collaboration and focused funding to the field of bipolar disorder. Multidisciplinary teams of scientists and clinicians, whose leads are at Yale University, Stanford University, New York Genome Center, and the Wyss Institute at Harvard University, will each receive grants of up to $4.5 million over three years to examine the fundamental mechanisms of bipolar disorder. Building on the success and enthusiasm from the field, BD² also announced the second round of funding for the program, inviting interested research teams to apply for grants of the same amount.

Key Points: 
  • "These teams of scientists will work within their own institutions and collaborate across teams to explore hypotheses on the biological causes of bipolar disorder."
  • These studies will expand knowledge about bipolar disorder biology and may translate that into pharmacological therapeutics and behavioral interventions.
  • BD² invites scientists across disciplines to learn more about and apply for this funding opportunity for bipolar disorder research.
  • In its first year, BD² has already dedicated more than $60 million in funding to research that accelerates scientific understanding of bipolar disorder and advances clinical care through cross-disciplinary collaboration, data sharing, and real-time learning.

Rhinostics Launches the ELEstic™/ELEbot™ Platform, Bringing Proven Automated Swab Workflows to Broad Diagnostics Systems

Retrieved on: 
Tuesday, July 25, 2023
Science, Other Science, Biotechnology, Hardware, Health, Medical Devices, Robotics, Technology, STI, COVID-19, Multimedia, LOD, Doctor of Philosophy, Collection, Laboratory, Wyss Institute, Wyss Institute for Biologically Inspired Engineering, Birth control

Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending ELEstic™ swab collection device combined with the groundbreaking ELEbot™ Decapper.

Key Points: 
  • Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending ELEstic™ swab collection device combined with the groundbreaking ELEbot™ Decapper.
  • The ELEbot Decapper provides 24-tube automated decapping of swab samples that can be placed upstream of these molecular testing platforms for sample elution and decapping prior to transferring the sample directly into the diagnostics testing system.
  • The ELEstic™ swab employs the proven stacked-ring head, developed at the Wyss Institute, with a successful track record testing millions of COVID-19 patient and medically collected samples.
  • Both the ELEstic and RHINOstic systems offer significant cost reductions to laboratory workflows through labor and reagent savings.

Emulate Unveils Chip-A1, Expanding Organ-on-a-Chip Technology Applications Within the Cancer and Cosmetics Markets

Retrieved on: 
Monday, June 26, 2023
Technology, Health Technology, Software, Biotechnology, Hardware, Health, Pharmaceutical, Data Management, Oncology, Product management, Tissue, Nature Biomedical Engineering, Therapy, Engineering, Harvard University, Chip, 3D, Cancer, Multimedia, Cosmetics, Cell, Doctor of Philosophy, Lung, Wyss Institute for Biologically Inspired Engineering, MD, Patient, Platform, Wyss Institute, Esophageal cancer, Bacteria, Gel, FDA, Skin, World Health Organization, Video game, Medical imaging, Vaccine, Emulate

Emulate, Inc ., the leading provider of next-generation in vitro models, today announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.

Key Points: 
  • Emulate, Inc ., the leading provider of next-generation in vitro models, today announced the launch of the Emulate Chip-A1™ Accessible Chip through an early access program.
  • View the full release here: https://www.businesswire.com/news/home/20230626795938/en/
    Exploded view of Chip-A1, showing the accessible culture chamber in the top channel, porous membrane, and serpentine bottom channel.
  • “From the beginning, our vision has been to enable more human-relevant research with Organ-on-a-Chip technology,” said Josiah Sliz, Vice President of Platform Development at Emulate.
  • Understanding a tumor’s microenvironment is key to regulating cancer progression and developing more effective therapies—and Chip-A1 will give researchers this capability.

Rhinostics and FutureMed Bring Innovative Dry Transport Technologies for Clinical Labs to Chile, developed amid the COVID-19 Pandemic

Retrieved on: 
Tuesday, June 20, 2023
Health, Other Health, Pharmaceutical, Other Science, Practice Management, Research, Infectious Diseases, General Health, Hospitals, Genetics, Science, COVID-19, Clinical Trials, Medical Supplies, DNA, Biochemistry, Coronavirus, VTM, Harvard Medical School, Patient, Laboratory, Collection, Wyss Institute, Hematology, Vertically transmitted infection, FDA, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry, Fine chemical, Vaccine, FutureM

The optimization of their operational capabilities and the incorporation of new technologies to overcome technical limitations in the pre-analytical and analytical stages, should be considered a permanent priority in health strategies.

Key Points: 
  • The optimization of their operational capabilities and the incorporation of new technologies to overcome technical limitations in the pre-analytical and analytical stages, should be considered a permanent priority in health strategies.
  • To this end, FutureMed, an advanced medical solutions company, is partnering with Rhinostics to bring Dry Transport Technologies to clinical laboratories in Chile.
  • "Several of the traditional limitations of clinical labs have now been resolved by these innovative products," explains Mateo Ibarcena, CEO of FutureMed and the exclusive representatives of Rhinostics for Chile.
  • Rhinostics' suite of sample collection devices is registered with the FDA as Class 1 medical devices.

Harvard’s Wyss Institute and Collaborative Fund cofound research lab to fund technology to combat climate change

Retrieved on: 
Tuesday, May 23, 2023
Wyss Institute for Biologically Inspired Engineering, Plastic, Collaborative Fund, Bakalar, Food, North American Vascular Biology Organization, Dandelion Energy, Partnership, Education, Research, Harvard University, Innovation system, Innovation, Harvard John A. Paulson School of Engineering and Applied Sciences, Modern Meadow, Harvard Medical School, Commonwealth Fusion Systems, Nature, Climate change, Patent, Robotics, Head, Wyss Institute, Applied science, Water, Judah, Bioinspiration, Growth, Climate, Hospital, Textile, Laboratory, Synthetic biology, Renewable energy, Management, Engineering, Wyss

Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.

Key Points: 
  • Collaborative Fund , a New York-based venture fund, is a leading source of capital and strategic support for entrepreneurs, businesses, and protocols pushing the world forward.
  • As part of the alliance, Collaborative Fund will provide $15 million to create a Laboratory for Sustainable Materials Research and Innovation at the Wyss Institute to support research into transformational technology with strong commercial potential.
  • Collaborative Fund has over a decade of experience investing in climate technology and recently launched a dedicated $200M climate fund, Collab SOS , to fuel a more sustainable economy across materials, ingredients, energy, and supply chains.
  • When it comes to climate change, there’s no time to waste,” said Sophie Bakalar, partner at Collaborative Fund.

Trestle Biotherapeutics Joins the Wellcome Leap HOPE Program

Retrieved on: 
Thursday, May 25, 2023
Biotechnology, Health, Science, Stem Cells, Research, Protalix BioTherapeutics, Kidney failure, Kidney, Harvard University, CSO, HOPE, Wellcome Trust, Human, Wyss Institute for Biologically Inspired Engineering, Dialysis, Transplant, Organization, Hope (programming language), Patient, LEAP, Immune system, Wyss Institute, Physiology, Pharmaceutical industry, Trestle

Trestle Biotherapeutics today announced that it has joined the Wellcome Leap HOPE program.

Key Points: 
  • Trestle Biotherapeutics today announced that it has joined the Wellcome Leap HOPE program.
  • HOPE (Human, Organs, Physiology & Engineering) is a $50M program focused on bioengineering complex human organs and immune system interactions.
  • Founded by Wellcome Trust in 2020, Wellcome Leap is a U.S. non-profit that builds and executes bold, unconventional programs designed to increase the number and speed of breakthroughs in human health.
  • Wellcome Leap and the HOPE program are the epitome of that and a perfect fit for a company like Trestle with ambitious goals,” said Trestle co-founder and CEO Ben Shepherd, Ph.D.
    Of the addition of Trestle to the HOPE program, HOPE Program Director Annie Moisan, Ph.D., said, "Trestle Biotherapeutics’ dedication to solving the urgent global challenge of kidney failure aligns perfectly with the HOPE goals.

Sappi North America Releases 2022 Sustainability Report, Achieves Top Sustainability Rating for Third Consecutive Year

Retrieved on: 
Tuesday, May 16, 2023
Sustainability, Packaging, Environment, Manufacturing, Science, Science Based Targets initiative, DSM, University, Bakul, Engineering, Harvard University, Sustainability reporting, Bose Corporation, Environmental health, Woman, Forest, Targets, UNSDG, Wyss Institute for Biologically Inspired Engineering, Microfluidics, Development, Wyss Institute, Apple, Sappi, United, Safety, Renewable energy, Research

The company also secured the EcoVadis Platinum sustainability rating for the third year in a row, keeping Sappi at the top 1% of companies rated for sustainability.

Key Points: 
  • The company also secured the EcoVadis Platinum sustainability rating for the third year in a row, keeping Sappi at the top 1% of companies rated for sustainability.
  • In 2022, the United Nation’s Sustainable Development Goals (UNSDG) continued to play an integral role in shaping Sappi’s business practices.
  • “I am proud of Sappi North America’s ongoing commitment to sustainability,” said Mike Haws, President and CEO, Sappi North America.
  • “Our strong achievements, together with our high-quality products serving customer demand, allowed Sappi to meet or beat all of our 2022 sustainability goals.”
    To read more of Sappi North America's 2022 Sustainability Report and request a copy, please visit: https://www.sappi.com/sustainability-and-impact .